Innovations in the management of epistaxis secondary to hereditary hemorrhagic telangiectasia: our evolution to injection sclerotherapy as the treatment of choice.

Front Allergy · 2024 · PMC11387978 · PMID 39262767

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significancep = 0.13not close (p > 0.1)

a median of 3.5 months (IQR: 1.5–6 months) in the non-sclerotherapy group, however, this difference did not reach statistical significance ( p = 0.13).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.